Fundraising Fox
OneOme
Minneapolis, US · Founded 2013 · Delaware LLC
Find your way into OneOme
Sign up to see every warm intro you have to OneOme
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OneOme team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OneOme is a precision medicine company that provides pharmacogenomics testing and analytics to healthcare providers, helping them optimize medication selection based on patients' genetic profiles. Co-founded by Mayo Clinic, the company serves healthcare teams and institutions globally seeking to improve patient outcomes and reduce costs through personalized medication decisions.
Founders & leadership
OneOme was founded in 2013 by Mayo Clinic.
MC
Mayo ClinicCo-founder
DJ
Danny J. CunaginExecutiveDanny J. Cunagin is an executive and company builder with two decades of experience in biomedical engineering and product development. He co-founded OneOme, a precision medicine company providing pharmacogenomics testing, and has co-founded and led multiple companies in biotechnology, diagnostics, and medical imaging, including Imbio (later acquired by 4DMedical) and Steady State Imaging (sold to GE Healthcare).
TD
Troy D. KoposchkeExecutive
JL
John Logan Black, IIINamed on SEC filing
MJ
Matthew J. FerberNamed on SEC filing
Board
Reported raises · per SEC filings
Form D private placements$3.8M disclosed across 4 rounds · 2015–2017
▶$100KraisedJun 2017 · 1 investors · Other TechnologyRule 506(b)
▶$100KraisedJun 2017 · 1 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Keith StewartDirector
- Harlan LangstraatExecutive Officer, Director
- Jeremy L. FrieseDirector
- Mark E. SylvesterExecutive Officer
- Troy D. KopischkeDirector
- Paul J. OwenExecutive Officer
- Offering amount
- $5M
- Amount sold
- $100K
- Minimum investment
- $50K
- Proceeds to insiders
- $960K
- First sale
- Jun 2017
- Incorporated
- Limited Liability Company, Delaware, 2013
- Federal exemptions
- 06b
▶$2.1MraisedOct 2016 · 11 investors · Other TechnologyRule 506(b)
▶$2.1MraisedOct 2016 · 11 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Mark E. SylvesterExecutive Officer
- Paul J. OwenExecutive Officer
- Keith StewartDirector
- Troy D. KopischkeDirector
- Jeremy FrieseDirector
- Harlan LangstraatDirector
- Offering amount
- $3.5M
- Amount sold
- $2.1M
- Minimum investment
- $40K
- First sale
- Sep 2016
- Incorporated
- Limited Liability Company, Delaware, 2013
- Federal exemptions
- 06b
▶$530KraisedOct 2016 · 11 investors · Other TechnologyRule 506(b)
▶$530KraisedOct 2016 · 11 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Paul J. OwenExecutive Officer
- Keith StewartDirector
- Mark E. SylvesterExecutive Officer
- Jeremy FrieseDirector
- Troy D. KopischkeDirector
- Harlan LangstraatDirector
- Offering amount
- $600K
- Amount sold
- $530K
- First sale
- Sep 2016
- Incorporated
- Limited Liability Company, Delaware, 2013
- Federal exemptions
- 06b
▶$1MraisedMay 2015 · 15 investors · Other TechnologyRule 506(b)
▶$1MraisedMay 2015 · 15 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- John Logan Black, IIIDirector
- Jeremy FrieseDirector
- Matthew J. FerberDirector
- Danny J. CunaginExecutive Officer
- Troy D. KoposchkeExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1M
- First sale
- Mar 2015
- Incorporated
- Limited Liability Company, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through OneOme went on to found or lead other companies.
Related companies · 9
MyomeMyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.
GenomindGenMedPro is a genetics-based medication management platform that analyzes 26 genes to identify drug-drug and gene-drug interactions across a patient's entire medication regimen. The platform serves healthcare providers and care teams to reduce prescribing errors, prevent adverse events, and optimize medication safety for complex polypharmacy cases.
One MedicalNASDAQ: ONEM; acquired by Amazon
healthOmeHealthŌme combines insurance with health navigation services to improve how patients access, finance, and receive precision healthcare.
LabcorpLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
IDbyDNAScalable, high throughput DNA sequencing platforms.
Quest DiagnosticsQuest Diagnostics is the world's leading provider of diagnostic information services, serving one in three adult Americans and half of US physicians and hospitals. The company offers diagnostic insights and testing services to consumers and healthcare providers to support health decision-making.
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
NucleomeNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.
Companies working in the same space as OneOme.
Frequently asked questions
- What does OneOme do?
- OneOme is a precision medicine company that provides pharmacogenomics testing and analytics to healthcare providers, helping them optimize medication selection based on patients' genetic profiles. Co-founded by Mayo Clinic, the company serves healthcare teams and institutions globally seeking to improve patient outcomes and reduce costs through personalized medication decisions.
- Who founded OneOme?
- OneOme was founded by Mayo Clinic in 2013.
- How much funding has OneOme raised?
- OneOme has disclosed $3.8M raised across 4 rounds.
- Where is OneOme headquartered?
- OneOme is headquartered in Minneapolis, US.